Cerebrospinal Fluid and Neuroimaging Biomarker Abnormalities Suggest Early Neurological Injury in a Subset of Individuals During Primary HIV Infection by Peluso, Michael J. et al.
M A J O R A R T I C L E
Cerebrospinal Fluid and Neuroimaging
Biomarker Abnormalities Suggest Early
Neurological Injury in a Subset of Individuals
During Primary HIV Infection
Michael J. Peluso,1 Dieter J. Meyerhoff,2 Richard W. Price,3 Julia Peterson,3 Evelyn Lee,3 Andrew C. Young,1
Rudy Walter,2 Dietmar Fuchs,4 Bruce J. Brew,5 Paola Cinque,6 Kevin Robertson,7 Lars Hagberg,8 Henrik Zetterberg,8
Magnus Gisslén,8 and Serena Spudich1
1Department of Neurology, Yale School of Medicine, New Haven, Connecticut; 2Department of Radiology and Biomedical Imaging, and 3Department of
Neurology, University of California–San Francisco School of Medicine; 4Division of Biological Chemistry, Innsbruck Medical University, Austria;
5Department of Neurology, University of New South Wales, Sydney, Australia; 6Department of Infectious Diseases, San Raffaele Scientific Institute,
Milan, Italy; 7Department of Neurology, University of North Carolina School of Medicine, Chapel Hill; and 8Department of Infectious Diseases, University
of Gothenburg, Sweden
Background. Cerebrospinal fluid (CSF) and neuroimaging abnormalities demonstrate neuronal injury during
chronic AIDS, but data on these biomarkers during primary human immunodeficiency virus (HIV) infection is limited.
Methods. We compared CSF concentrations of neurofilament light chain, t-tau, p-tau, amyloid precursor proteins,
and amyloid-beta 42 in 92 subjects with primary HIV infection and 25 controls. We examined relationships with
disease progression and neuroinflammation, neuropsychological testing, and proton-magnetic resonance spectroscopy
(MRS)–based metabolites.
Results. Neurofilament light chain was elevated in primary HIV infection compared with controls (P = .0004) and
correlated with CSF neopterin (r = 0.38; P = .0005), interferon gamma-induced protein 10 (r = 0.39; P = .002), white
blood cells (r = 0.32; P = .004), protein (r = 0.59; P < .0001), and CSF/plasma albumin ratio (r = 0.60; P < .0001). Neurofi-
lament light chain correlated with decreased N-acteylaspartate/creatine and glutamate/creatine in the anterior cingulate
(r =−0.35, P = .02; r =−0.40, P = .009, respectively), frontal white matter (r =−0.43, P = .003; r =−0.30, P = .048, respec-
tively), and parietal gray matter (r =−0.43, P = .003; r =−0.47, P = .001, respectively). Beta-amyloid was elevated in the
primary infection group (P = .0005) and correlated with time infected (r = 0.34; P = .003). Neither marker correlated
with neuropsychological abnormalities. T-tau and soluble amyloid precursor proteins did not differ between groups.
Conclusions. Elevated neurofilament light chain and its correlation with MRS-based metabolites suggest early neu-
ronal injury in a subset of participants with primary HIV infection through mechanisms involving central nervous
system inflammation.
Keywords. HIV/AIDS; primary HIV infection; biomarkers; neurological damage; neurofilament light chain;
magnetic resonance spectroscopy.
Although the incidence of human immunodeficiency
virus (HIV)–associated dementia has decreased with
the widespread use of combination antiretroviral ther-
apy (cART), patients continue to experience varying
degrees of HIV-associated neurological disorder [1].
Because even mild impairment affects quality of life [2],
the neurological consequences of HIV infection have
gained increased attention, as has the need to distin-
guish active processes from static abnormalities in the
central nervous system (CNS) of these patients [3].
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Cerebrospinal fluid (CSF) biomarkers, the altered concentra-
tions of which have been associated with neurodegenerative
processes, include neurofilament light chain, a structural com-
ponent of myelinated axons; t-tau, a microtubule-associated
protein promoting axon stability; its hyperphosphorylated
component, p-tau; soluble amyloid precursor proteins-α and
-β, products of amyloid processing pathways; and soluble
amyloid-beta 42. Thesemarkers are abnormal inHIV-associated
dementia [4–7] and neuroasymptomatic advanced AIDS [4, 8–10].
However, the extent of neurological injury during presymptom-
atic HIV infection, especially early infection, is not completely
understood. Limited data suggest that neurological injury
occurs in some individuals during primary HIV infection [4],
defined as the first year after viral transmission. During primary
infection, up to 10% of individuals develop neurological signs
and symptoms, and the virus can be detected in CSF and brain
tissue [11]. HIV infiltrates the CSF as early as 8 days posttrans-
mission [12], and immune activation occurs throughout
primary infection [13], suggesting the potential for CNS injury
in the earliest stages of infection.
Proton-magnetic resonance spectroscopy (MRS) is a non-
invasive imaging modality that has been used to monitor
neuronal injury through analysis of metabolite abnormalities.
N-acetylaspartate and glutamate, often expressed relative to
creatine levels, are markers of neuronal health that deplete with
injury [14, 15]. Work in macaques suggests that the neuronal
manifestations of HIV occur rapidly but are reversible with
cART [16]. Human studies have shown that N-acetylaspartate/
creatine ratios decline in chronic untreated HIV infection
(eg, [17]) and improve [18], but may not normalize, with
therapy [19]. Recently, we have shown with MRS that metabolite
levels do not differ significantly between controls and patients
with primary HIV infection at baseline but that abnormalities in
the latter worsen over time and improve with early cART [20].
In this study, we quantified CSF biomarkers as a proxy for
neuronal injury in individuals with primary HIV infection and
compared them with those in HIV-uninfected controls. We
hypothesized that primary HIV infection is characterized by
increased concentrations of CSF neurofilament light chain and
that this increase correlates with elevated concentrations of CSF
markers of neuroinflammation and decreased concentrations
of N-acetylaspartate and glutamate measured by MRS. We
expected tau and amyloid levels in primary HIV infection to
not differ from controls, as has been previously reported [7] in
chronically HIV-infected, neuroasymptomatic individuals.
METHODS
Study Design and Participants
This cross-sectional study enrolled 92 cART-naive participants
with primary HIV infection between 1987 and 2011 in
San Francisco, California; Gothenburg, Sweden; and Sydney,
Australia.
Participants were referred from physicians or counseling and
testing centers based on known or suspected recent HIV infec-
tion. Participants were eligible if they met criteria for primary
infection based on nucleic acid testing and less-sensitive
enzyme-linked immunosorbent assay according to the standard
serologic testing algorithm for recent HIV seroconversion
(STARHS) [21]. Estimated number of days posttransmission
was calculated assuming exposure occurred 14 days before the
acute retroviral syndrome [22] or, in the absence of symptoms,
as halfway between the last negative and the first positive test
result.
A neurologist screened for exclusion criteria including active
unrelated neurological disorders. Subjects were screened with
standardized inventories for mental illness and substance
abuse, and presence of these was recorded. Data was excluded
from the analysis if participants demonstrated signs of intoxica-
tion and/or reported substance use on the visit day.
Data about CSF HIV RNA and neurological symptoms have
been previously reported in a subset of participants [13, 23], as
have neurofilament light chain results in 16 subjects using a dif-
ferent, less-sensitive assay [4]. Twenty-five HIV-uninfected
volunteers provided comparison samples. All participants pro-
vided written informed consent in studies approved by the in-
stitutional review board or equivalent entity at each institution.
Specimen Sampling, Processing, and Laboratory Analysis
Participants underwent detailed neurological history and physi-
cal examination, as well as collection of blood and CSF speci-
mens between 7:30 AM and 12:00 PM. HIV RNA levels in cell-
free CSF and plasma were measured by the ultrasensitive Roche
Amplicor HIV-1 Monitor PCR, Cobas TaqMan RealTime
HIV-1, or the Abbott RealTime HIV-1 assays at local sites. CSF
total white blood cells (WBCs) and protein and CD4+ and
CD8+ T-lymphocyte counts were measured on fresh samples
by flow cytometry.
Cell-free CSF and blood plasma were aliquoted and stored
within 6 hours of collection in −70°C or −80°C freezers moni-
tored by National Institutes of Standards and Technology–
certified thermometers. Neurofilament light chain concentra-
tion was measured using a new, highly sensitive, 2-site enzy-
matic quantitative immunoassay with a lower limit of detection
of 50 ng/L in the laboratory of Dr Zetterberg. The upper-
normal CSF neurofilament light chain levels at the laboratory
were <380 (in subjects aged <30 years), <560 (in subjects aged
30–39 years), <890 (in subjects aged 40–59 years), and <1850
ng/L (in subjects aged >59 years) [24]. Reference values were
obtained in the Zetterberg laboratory based on the analysis of
108 neurologically healthy HIV-uninfected individuals. Detec-
tion of t-tau, beta-amyloid, and soluble amyloid precursor pro-
teins-α and -β used standard enzyme-linked immunosorbent
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assays in the Zetterberg laboratory. Blood and CSF neopterin
measurements were performed in the laboratory of Dr Fuchs
using commercially available immunoassays; interferon
gamma-induced protein 10 (IP-10) and monocyte chemotactic
protein 1 (MCP-1) measurements were performed locally using
commercially available assays.
Proton-Magnetic Resonance Spectroscopy
After standard clinical MR imaging, proton (1H)-MRS was
performed on a 4-Tesla Siemens/Bruker scanner in 53 primary
HIV infection participants at baseline in the neuroimaging lab-
oratory of Dr Meyerhoff. Water-suppressed short echo-time
(TE) single-volume STEAM spectra (TR/TE/TM = 2000/12/10
ms; spectral width = 2000 Hz; spectral data size = 2048 points;
128 scans; total acquisition time = 4:16 min) were acquired
from 4 volumes selected on sagittal T1-weighted and axial
T2-weighted images. Different tissue types were targeted: ante-
rior cingulate (20 × 20 × 20 mm3), frontal white matter
(15 × 25 × 20 mm3), basal ganglia (17 × 35 × 15 mm3), and pa-
rietal gray matter (25 × 20 × 20 mm3). We chose these areas
based on acute simian immunodeficiency virus studies in ma-
caques that had shown changes in these regions [16, 25, 26].
Meyerhoff and others have previously described most MRS
processing methods [27]. Briefly, all MR imaging and single-
volume 1H MRS data were stored in an SQL database and were
processed and analyzed with updated software tools developed
in-house [28] or in routine use for many years. The spectral
fitting software SITOOLS used a parametric model of known
metabolite resonances and modeled spectral components, in-
cluding those of macromolecules, to fit all spectral resonances
and nonparametric parameters to the baseline. A priori spectral
information used the frequencies, phases, and approximate rel-
ative amplitudes of all major metabolites at 4-Tesla and also in-
cluded resonances for macromolecules. The obtained raw
metabolite signal integrals were corrected for MR imaging–
derived tissue and CSF contributions to the MRS volumes,
corrected for different receiver and transmitter settings when
necessary, and then normalized to the cerebral water signal ob-
tained from the corresponding volumes. For each metabolite,
these adjusted signal integrals (“peak areas”) were converted to
metabolite ratios: glutamate/creatine, myo-inositol/creatine, N-
acetylaspartate/creatine, and choline-containing metabolites/
creatine. We excluded spectra from analyses if they exhibited
poor signal-to-noise ratios, excessive water signal, or other sig-
nificant artifacts. High-field proton MRS at 4-Tesla has highly
sensitive signal-to-noise detection and thus allowed us to deter-
mine individual peaks of glutamate and glutamine instead of
the combined “Glx” peak.
Neuropsychological Testing
Neuropsychological testing was performed only at the
San Francisco site, and all participants were fluent in English.
At baseline, a trained psychometrist administered a neuropsy-
chological testing battery composed of motor (timed gait,
finger tap nondominant hand, grooved pegboard), processing
speed (trail making A, digit symbol), executive function (trail
making B, verbal fluency), learning (Rey Auditory Verbal
Learning Test, figural memory), and memory (Rey Auditory
Verbal Learning Test delay, figural memory delay) domains. To
control for the social and demographic variability in the group,
z scores for neuropsychological testing were used for all analy-
ses, which were derived from comparing raw scores to age-,
sex-, ethnicity-, and level-of-education–matched norms. We
calculated a z domain score by averaging all z scores within that
domain and calculated an NPZ-4 score by summing grooved
pegboard, digit symbol, finger tapping, and timed gait. A total z
score was calculated as a composite of all tests, and a global
deficit score was calculated in the standard manner [29].
Statistical Analyses
Nonparametric descriptive statistics used the Mann–Whitney
U test and the Kruskal–Wallis test with post hoc testing correct-
ed with Dunn’s multiple comparison, all performed with SPSS
version 19.0 and GraphPad Prism version 5.0d. Correlations
between measured parameters employed Spearman’s rank
correlation coefficient; parametric correlations and linear re-
gression were also conducted for illustrative purposes. A multi-
variable regression model to investigate independent predictors
of CSF neurofilament light chain included age, CSF neopterin,
WBC, protein, IP-10, and CSF/plasma albumin ratio; these pa-
rameters had been identified as significant predictors in both
the parametric and nonparametric univariable models.
RESULTS
Study Participant and HIV Disease Characteristics
Table 1 shows background clinical and demographic informa-
tion for primary HIV infection participants (n = 92) and HIV-
uninfected controls (n = 25). HIV-infected participants were a
median of 3.1 months posttransmission and were younger and
more likely to be male than the controls. Eight of 92 (8.7%) par-
ticipants in the primary HIV infection group had previously ex-
perienced ≥1 neurological symptoms during seroconversion,
and the majority harbored infection with HIV subtype B [13].
CSF Markers of Neuronal Injury During Primary HIV Infection
Figure 1 shows comparisons of 6 CSF biomarkers between the
2 groups. Median neurofilament light chain in 82 primary HIV
infection participants was elevated compared with 20 controls
(P = .0004; Figure 1A). When stratified by age, 36 of 82 (44%)
participants had neurofilament light chain elevations above the
upper limit of normal for their age group: 13 of 24 (54%) aged
<30 years, 12 of 24 (50%) aged 30–39 years, 10 of 31 (32%)
aged 40–59 years, and 1 of 3 (33%) aged >59 years.
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P-tau was elevated in 66 primary HIV infection participants
compared with 23 controls (P = .016, Figure 1B). There were no
significant differences between groups in t-tau or soluble
amyloid precursor proteins-α and -β (Figure 1C–E). Amyloid-
beta 42 was elevated in 73 primary HIV infection participants
compared with 23 controls (P = .0005; Figure 1F).
Participants who had experienced neurologically sympto-
matic seroconversion did not have higher neurofilament light
chain, p-tau, or amyloid-beta 42 than those who had not. Even
when previously symptomatic participants were excluded, these
biomarkers remained elevated in the primary infection group
compared with controls.
Determinants of Elevated Neurofilament Light Chain During
Primary HIV Infection
CSF neurofilament light chain correlated with concentrations
of inflammatory markers including CSF neopterin (r = 0.38;
P = .0005) and IP-10 (r = 0.39; P = .002), WBC count (r = 0.32;
P = .004), protein (P = .59; P < .0001), and CSF/plasma albumin
ratio (r = 0.60; P < .0001). Significant correlations were not
found between neurofilament light chain and CD4+ T-cell
count, estimated days postinfection at sampling, plasma and
CSF HIV RNA levels (Figure 2), or CSF MCP-1 (not shown).
High neurofilament light chain levels correlated with low
N-acetylaspartate/creatine and glutamate/creatine ratios in the
anterior cingulate (r = −0.35, P = .02; r =−0.40, P = .009, re-
spectively), frontal white matter (r = −0.43, P = .003; r =−0.30,
P = .048, respectively), and more strongly in the parietal gray
matter (r = −0.43, P = .003; r = −0.47, P = .001, respectively;
Figure 3). N-acetylaspartate/creatine and glutamate/creatine
ratios were correlated across these 3 regions (r > 0.50; P < .001).
No significant correlations were present between neurofilament
Figure 1. A–F, Cerebrospinal fluid biomarkers of neuronal injury in the primary human immunodeficiency virus (HIV) infection group and HIV-uninfected
control group. Abbreviations: CSF, cerebrospinal fluid; HIV-, human immunodeficiency virus–uninfected control group; NFL, neurofilament light chain; PHI,
primary human immunodeficiency virus infection group; p-tau, hyperphosphorylated tau; sAPP, soluble amyloid precursor protein; t-tau, total tau.
Table 1. Demographic and Descriptive Characteristics of
Primary HIV Infection Participants and HIV-Uninfected Controls
PHI (n = 92)
HIV-uninfected
(n = 25) P Value
%Male 95.2% 80% .03
Age, years 36 (28–46) 43 (40–49) .001
Estimated days of
infection 92 (52–152)
. . . . . .
CD4 count, cells/uL 536 (392–682) 836 (703–1056) <.0001
Log10 plasma VL 4.6 (4.0–5.2) . . . . . .
Log10 CSF VL 2.9 (2.0–3.6) . . . . . .
CSF protein, mg/dL 41 (32–53) 47 (33–56) .71
CSFWBCs, cells/uL 6 (2–11) 1 (0–2.5) <.0001
% ARS neuro
symptoms
8.7% . . . . . .
Values are shown as median (IQR) except where noted.
Abbreviations: ARS, acute retroviral syndrome; CSF, cerebrospinal fluid; HIV,
human immunodeficiency virus; PHI, primary HIV infection; VL, viral load;
WBC, white blood cells.
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light chain and glutamate/creatine or N-acetylaspartate/crea-
tine in the basal ganglia or with myo-inositol/creatine or
choline/creatine from any region.
Multivariable linear regression modeling was used to identify
independent predictors of CSF neurofilament light chain in
primary infection participants and revealed independent corre-
lations with age, CSF WBC, and CSF/plasma albumin ratio
(adjusted r2 = 0.624).
Determinants of Elevated Amyloid-Beta 42 During Primary HIV
Infection
Amyloid-beta 42 did not correlate with age in the primary HIV
infection group but did correlate with levels of soluble amyloid
precursor proteins-α and -β (r = 0.27, P = .03; r = 0.30, P = .02,
respectively) and with days of infection (r = 0.34; P = .003).
There were no significant correlations between amyloid-beta 42
and plasma or CSF viral load, CSF/plasma albumin ratio, or
Figure 2. A–H, Correlates of neurofilament light chain levels in primary human immunodeficiency virus infection. r represents the Spearman correlation
coefficient and corresponding P value. Solid lines represent best-fit regression line, and dashed lines represent 95% confidence intervals. Abbreviations:
CSF, cerebrospinal fluid; IP-10, interferon gamma-induced protein 10; NFL, neurofilament light chain; WBC, white blood cell.
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CSF protein, neopterin, MCP-1, or IP-10 (Figure 4). Notably,
neurofilament light chain and amyloid-beta 42 did show a
modest correlation (r = 0.29; P = .02).
Neuropsychological Testing
At baseline, there were no significant correlations between
CSF neurofilament light chain and composite z scores for
motor function, processing speed, memory, or learning.
Neurofilament light chain and the composite z score for execu-
tive function tended to be correlated (r = 0.27; P = .049).
DISCUSSION
Our findings demonstrate that biomarkers of neuronal injury, in-
cluding neurofilament light chain and amyloid-beta 42, are ab-
normal in the CSF of a subset of individuals with primary HIV
Figure 3. A–H, Correlations of neurofilament light chain levels with regional proton-magnetic resonance spectroscopy–derived metabolite ratios. r rep-
resents the Spearman correlation coefficient and corresponding P value. Solid lines represent best-fit regression line, and dashed lines represent 95% con-
fidence intervals. Abbreviations: Glu/Cr, glutamate/creatine; NAA/Cr, N-acetylaspartate/creatine; NFL, neurofilament light chain.
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infection and that neurofilament light chain concentration corre-
lates with established MRS markers of neuronal injury. This sug-
gests that neuronal injury, in addition to viral replication [11],
immune activation [5, 30], and blood–brain barrier break-
down [11] occurs early in the course ofHIV infection in some indi-
viduals. The association of neurofilament light chain withmarkers
of inflammation suggests a relationship between injury and im-
mune activation. The finding that MRS measures of cortical and
white matter N-acetylaspartate/creatine and glutamate/creatine
demonstrate associations with CSF neurofilament light chain
concentrations is the first data that we know of that relate nonin-
vasive neuroimaging markers of neuronal injury to CSF neural
marker abnormalities in HIV infection. Neuronal health and
stability appears compromised in some brain regions in the earli-
est stages of HIV infection. The lack of correlation between neu-
rofilament light chain levels and common neuropsychological
test performance may suggest that neurofilament light chain
elevation reflects subclinical injury during this stage of infection.
Figure 4. A–G, Correlates of beta-amyloid in primary human immunodeficiency virus infection. Solid lines represent best-fit regression line, and dashed
lines represent 95% confidence intervals. Abbreviations: CSF, cerebrospinal fluid; NFL, neurofilament light chain; sAPP, soluble amyloid precursor protein.
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Neurofilament Light Chain
Neurofilament light chain concentration serves as a sensitive
indicator of CNS axonal injury in neurodegenerative disorders
including Alzheimer disease, atypical Parkinsonian syndromes,
and amyotrophic lateral sclerosis [31, 32], as well as in multiple
sclerosis [33] and traumatic brain injury [34]. CSF neurofila-
ment light chain concentrations increase in untreated in-
dividuals with HIV-associated dementia and neurological
opportunistic infections [4]. Neurofilament light chain decreases
with cART initiation, increases with cART discontinuation,
and may serve as a predictor for which individuals go on to
develop neurological disease [8, 35, 36].
Previously, neurologically asymptomatic HIV-1–infected
individuals with chronic infection and CD4+ T-cell counts
>200 cells/µL were thought not to have elevated CSF neurofila-
ment light chain, and this threshold was thought to be sufficient
to prevent CNS disease [36]. However, further work in chroni-
cally infected subjects indicated that HIV-infected individuals
with CD4+ T-cell counts above 200 cells/µL can have elevations
in neurofilament light chain upon the cessation of cART [8],
that lower CD4+ T-cell counts tend to be associated with higher
neurofilament light chain [4], and that very low CD4+ T-cell
counts are associated with increased neurofilament light chain
concentrations [10].
Previous work using a less-sensitive assay identified elevated
neurofilament light chain in 4 of 16 (25%) subjects with pri-
mary HIV infection but showed no significant difference com-
pared with controls [4]. Our findings using a more-sensitive
assay demonstrate increased neurofilament light chain in the
group comparison, as well as in 44% of participants who had
elevations in this marker compared with the age-appropriate
upper limit of normal. This suggests that, in at least a subset of
participants, neurologic injury occurs during primary HIV in-
fection even in subjects without neurological symptoms during
seroconversion. Along with CSF HIV RNA and inflammatory
markers, elevated neurofilament light chain levels may help
identify individuals with an active disease process. Because it
has been suggested that neurofilament light chain can predict
neurologic disease progression [35], it is possible that neurofila-
ment light chain may identify individuals that might benefit
from early pharmacologic intervention aimed at protecting the
brain from neuronal injury.
A significant proportion of these participants did not have
elevated neurofilament light chain, suggesting possibly that an
unknown viral or host factor increases the susceptibility of
certain individuals to neurological injury during this period.
Correlates of Elevated Neurofilament Light Chain During
Primary HIV Infection
Overall, the results suggest an association between neurofila-
ment light chain and inflammatory processes. It is notable that
such an association did not exist with amyloid-beta 42,
implying that neurofilament light chain might be a more spe-
cific marker for inflammatory injury. During primary infec-
tion, neurofilament light chain was not associated with CD4+
T-lymphocyte count, which may reflect the fact that CD4
count during this period is a correlate of acute systemic
immune response to HIV acquisition rather than duration and
progression of infection. Neurofilament light chain also did
not strongly associate with markers of infection, including
plasma and CSF HIV RNA. However, because the N-acetylas-
partate/creatine ratio is a putative marker of neuronal health,
our results suggest that declining neuronal health is associated
with increased neuronal injury as identified through elevated
CSF neurofilament light chain. This is particularly true in the
parietal gray matter and frontal white matter, consistent with
studies in animal models [25, 26].
We also found a negative association between the glutamate/
creatine ratio and neurofilament light chain. Elevated gluta-
mate/creatine is a putative marker for excitotoxicity, but it is
also considered a marker of neuronal integrity (eg, [15]). Previ-
ous studies have shown that HIV-infected individuals with cog-
nitive deficits have lower glutamate/creatine levels, particularly
in the parietal gray matter but not the frontal white matter [15].
Here, we found a similar regional specificity in that high neuro-
filament light chain levels correlate strongly with low gluta-
mate/creatine in the parietal gray matter but not in the frontal
white matter. The strong correlations between glutamate/crea-
tine and N-acetylaspartate/creatine ratios across all brain
regions emphasize the value of these metabolites in the assess-
ment of neuronal health and suggest that the consistent region-
al metabolite correlations with neurofilament light chain are
meaningful.
We found no convincing correlation between CSF neurofila-
ment light chain and performance on most cognitive domains
assessed by a circumscribed battery of neuropsychological tests.
However, an modest association between higher neurofilament
light chain and poorer performance in tests of executive func-
tion may reflect a relationship between neural injury and im-
pairment of this cognitive domain during early infection.
Tau and Amyloid Proteins
Tau and amyloid proteins are valuable in the identification of
neurodegenerative disorders [37–39], but their use in HIV in-
fection is less clear. T-tau and p-tau patterns in HIV-associated
neurologic disorder and HIV-associated dementia are inconsis-
tent [7, 40, 41]. In this study, elevated p-tau occurred in the
context of unchanged t-tau, a pattern different from chronic
AIDS [41], Alzheimer disease [39], and Creutzfeldt–Jakob
disease [42]. The difference is weaker than that for neurofila-
ment light chain or amyloid-beta 42, and we are therefore
unable to conclude whether t-tau and p-tau could be useful
measures of neuronal injury in primary HIV infection.
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Amyloid precursor proteins are cleaved by secretases into
soluble amyloid precursor proteins-α and -β; cleavage to the -β
form generates a molecule leading to amyloid-beta 42 [7].
Amyloid-beta 42 decreases in Alzheimer disease [38] and in
HIV-associated neurologic disorder [43], HIV-associated de-
mentia [41], and CNS opportunistic infections [7]. Pathological
studies show amyloid deposition in brain tissue of HIV-
infected individuals [44], but this marker has not been explored
in primary HIV infection.
The elevation in amyloid-beta 42 could be accounted for by
a number of mechanisms. It is unlikely due to the age of the
participants in each group, as median levels for controls is con-
cordant with those for young controls in other studies [7] and
themedian value in primaryHIV infection participants is higher
than in neuroasymptomatic HIV-infected individuals [7].
Elevated CSF amyloid-beta 42 has recently been associated
with cerebral inflammation [45]. Here, amyloid-beta 42 did not
correlate with markers of neuroinflammation in primary HIV
infection participants, but the markers we measured differed
from those for which correlations have been identified (tumor
necrosis factor α, interleukin 6, or interleukin 8) in other
studies [45].
Limitations
This cross-sectional study captured participants at a single
timepoint; future work with longitudinal data will help deter-
mine how these biomarkers change with time. Our study par-
ticipants were almost exclusively men, which poses a problem
for generalizing these results to HIV-infected women. Because
the median duration of infection was 3.1 months, it is unclear
when during primary HIV infection these biomarker abnor-
malities begin to occur. We defined our hypotheses before
conducting our analyses, but still made many statistical com-
parisons; because of this, we attempted to exercise restraint in
statistical interpretation and to correct for multiple compari-
sons. Nevertheless, we find the data, particularly in the con-
trasts in correlated variables between neurofilament light chain
and amyloid-beta 42, to be a convincing starting point for
further exploration of the mechanisms of neurologic injury
during primary HIV infection.
Implications
Our finding of neuronal injury during primary HIV infection
has important implications for the understanding of HIV patho-
genesis and management. Previously, neuronal injury was
thought to be a product of prolonged infection. The presence of
abnormally elevated CSF neurofilament light chain levels in 44%
of our participants adds to a growing body of evidence suggest-
ing that neurological injury begins in primary HIV infection.
Thus, although initiation of cART often occurs once an immu-
nological threshold is crossed after several years of infection,
CNS injury might begin soon after seroconversion in the setting
of early neuroinvasion and immune activation. If this were the
case, it would provide additional rationale for early pharmaco-
logical intervention in HIV infection aimed at mitigating CNS
injury.
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